[1.] Kiliç, S., et al., Ratio of free to total prostate-specific antigen in patients with prostatic intraepithelial neoplasia. European urology, 1998. 34(3): p. 176-180.
[2.] Balk, S.P., Y.-J. Ko, and G.J. Bubley, Biology of prostate-specific antigen. Journal of clinical oncology, 2003. 21(2): p. 383-391.
[3.] Luboldt, H.-J., J.F. Schindler, and H. Rübben, Age-specific reference ranges for prostate-specific antigen as a marker for prostate cancer. EAU-EBU update series, 2007. 5(1): p. 38-48.
[4.] Caplan, A. and A. Kratz, Prostate-specific antigen and the early diagnosis of prostate cancer. Pathology Patterns Reviews, 2002. 117(suppl_1): p. S104-S108.
[5.] Murthy, V., et al., Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. Clinical biochemistry, 2016. 49(1-2): p. 79-84.
[6.] Arthur, F., et al., Prostate cancer screening in Ghana-a clinical benefit? Journal of Science and Technology (Ghana), 2006. 26(1): p. 1-7.
[7.] Feldman, A.T. and D. Wolfe, Tissue processing and hematoxylin and eosin staining, in Histopathology. 2014, Springer. p. 31-43.
[8.] Mellinger, G.T., D. Gleason, and J. Bailar, The histology and prognosis of prostatic cancer. The Journal of urology, 1967. 97(2): p. 331-337.
[9.] Epstein, J.I., An update of the Gleason grading system. The Journal of urology, 2010. 183(2): p. 433-440.
[10.] Nan, L.B., X.T. Yin, and J.P. Gao, Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution. Med Sci Monit, 2019. 25: p. 8345-8351.
[11.] Froehner, M., et al., Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int, 2006. 76(1): p. 27-30.
[12.] Fryczkowski, M., et al., Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer. Dis Markers, 2018. 2018: p. 3852401.
[13.] Wang, Q., et al., The establishment and evaluation of a new model for the prediction of prostate cancer. Medicine (Baltimore), 2017. 96(11): p. e6138.
[14.] Gelmini, S., et al., Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clinical Chemistry and Laboratory Medicine (CCLM), 2003. 41(3): p. 261-265.
[15.] Prcic, A., E. Begic, and M. Hiros, Usefulness of total PSA value in prostate diseases diagnosis. Acta Informatica Medica, 2016. 24(3): p. 156.
[16.] Alcaraz, A., et al., Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. European urology, 2009. 55(4): p. 864-875.
[17.] Nakamura, T., et al., The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res, 2003. 63(19): p. 6543-6.
[18.] Lyu, J., et al., Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population. Biomed Res Int, 2019. 2019: p. 9306803.
[19.] Antwi, E., et al., Improved prediction of gestational hypertension by inclusion of placental growth factor and pregnancy associated plasma protein-a in a sample of Ghanaian women. Reprod Health, 2018. 15(1): p. 56.
[20.] Brown, C.D. and H.T. Davis, Receiver operating characteristics curves and related decision measures: A tutorial. Chemometrics and Intelligent Laboratory Systems, 2006. 80(1): p. 24-38.
[21.] Heyns, C., Is prostate cancer more common and more aggressive in African men? African journal of Urology, 2008. 14(2): p. 66-74.
[22.] Chu, K., An introduction to sensitivity, specificity, predictive values and likelihood ratios. Emergency Medicine, 1999. 11(3): p. 175-181.
[23.] Coelho, F.F., et al., Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer. Genet Mol Res, 2015. 14(4): p. 13519-31.